According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical business. It concentrates on discovering and also developing little particle medication prospects to deal with cancer cells. The Company‘s items under various phases of growth include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “
Several various other equities research experts likewise just recently discussed the company. Noble Financial reissued a “purchase” ranking and also released a $11.00 price objective on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 and also established a “buy” ranking on the stock in a research note on Tuesday, September 28th.
NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. The business has a 50 day moving typical rate of $2.90 and a two-hundred day relocating average rate of $4.16. The firm has a market cap of $46.76 million, a P/E ratio of -1.82 and also a beta of 1.67.
Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly earnings outcomes on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) revenues per share for the quarter, covering experts’ consensus price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% as well as a negative internet margin of 8,294.27%. The firm had revenue of $0.06 million throughout the quarter, compared to the agreement price quote of $0.06 million. Throughout the very same quarter in the prior year, the company posted ($ 0.45) EPS. En masse, research analysts forecast that Onconova Therapeutics will certainly post -1.18 EPS for the existing year.
A number of hedge funds have actually recently bought and sold shares of ONTX. GSA Capital Partners LLP bought a brand-new position in Onconova Therapeutics throughout the 3rd quarter worth $922,000. Hudson Bay Funding Management LP got a new placement in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC got a new setting in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC acquired a brand-new placement in shares of Onconova Therapeutics in the third quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP purchased a new placement in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds as well as other institutional financiers have 13.36% of the business’s stock.
Concerning Onconova Therapeutics
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which takes part in the identification as well as growth of oncology therapeutics. It focuses on uncovering as well as establishing tiny particle medication candidates to treat cancer cells. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA
. Obtain a cost-free duplicate of the Zacks research record on Onconova Therapeutics (ONTX).
For additional information concerning research offerings from Zacks Investment Research, go to Zacks.com.
This immediate information alert was created by narrative scientific research technology as well as economic data from Market in order to provide viewers with the fastest and also most precise reporting. This tale was assessed by Market’s content team prior to magazine.
SHOULD YOU INVEST $1,000 IN ONCONOVA THERAPEUTICS TODAY?
Prior to you take into consideration Onconova Therapeutics, you’ll want to hear this.
Market monitors Wall Street’s top-rated as well as ideal performing research analysts and the stocks they recommend to their clients every day. Market has actually identified the five stocks that top experts are quietly whispering to their clients to buy now prior to the more comprehensive market catches on … as well as Onconova Therapeutics had not been on the listing.
While Onconova Therapeutics presently has a “Buy” rating amongst analysts, premier analysts believe these five stocks are better acquires.